Skip to content

Addiction research published in 2025

Page 3 of 8: studies 41 to 60 of 156, newest first. Back to the addiction overview

Studies

Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review

Psychedelic Medicine October 8, 2025 Pim B. van der Meer, Nout Schukking, Miranda G. Dik et al.

Background: Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance-related disorder (i.e., gambling disorder) in order to provide a comprehensive overview of the available...

Mindfulness-Based Intervention Improves Depression, Anxiety, and Quality of Life in Unstably-Housed Women with PTSD and Substance Use Disorder

Mindfulness October 1, 2025 Dana Rose Garfin, Cordelia Lee, Branislav Jovanovic et al.

Abstract Objective This study sought to evaluate the efficacy of Mindfulness-based Stress Reduction (MBSR) on symptoms of posttraumatic stress, depression, anxiety, and perceived stress and quality of life in unstably-housed women undergoing substance use disorder (SUD) treatment. Despite the potential for MBSR to be a helpful adjunct to ongoing care, prior research on the benefit of MBSR in...

Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 1, 2025 Marta L.c. Palhas, Rémi Corne, Raymond Mongeau 4 citations

After years of restrictions due to concerns about their potentially harmful effects, research on psychedelics has entered a new era. Increasing attention has been directed toward their immense therapeutic potential, particularly for psychiatric disorders. Pre-clinical and clinical studies have consistently demonstrated that psychedelic treatments produce therapeutic effects within hours of...

The Impact of Yoga and Mindfulness on the Mind and Its Implications for Health and Illness

International Journal of Yoga Sports and Health Sciences September 30, 2025 Nuria Tello Jiménez

In today's times it is necessary to integrate a holistic understanding of the human body, remembering the importance that mind and emotions have in the physical appearance of the body. The purpose of this paper is to provide a comprehensive overview of the benefits of consistent yoga practice and to assess the results of a few chosen articles that investigate the therapeutic effects of yoga....

The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews.

Brain Sciences September 28, 2025 Sabrina Correa Da Costa, Nicholas L. Bormann, Tyler Oesterle et al. 3 citations

Background: Substance use disorders (SUDs) are highly prevalent, affecting over 48.5 million Americans. Available treatments for SUD remain insufficient, and many patients do not respond to existing interventions despite adequate adherence to treatments. While novel therapies for SUD are urgently needed, the use of psychedelic drugs for the treatment of SUDs has shown promise. Objectives: This...

DOI: 10.3390/brainsci15101056 (opens in new tab) Full text (opens in new tab) Psychedelics Addiction treatment Substance use disorders Therapeutic research

Co-Boost: boosting and guiding neuroplasticity by combining ketamine with neurofeedback-assisted learning—towards an individualised and integrated pharmaco-psychotherapy for cocaine addiction: study protocol for a randomised, placebo-controlled, double-blind, parallel-group, single-centre trial

Trials September 25, 2025 Anna Trippel, Ladina P Gubser, Etna Engeli et al. 1 citation

BACKGROUND: Cocaine is the most frequently used stimulant worldwide, with increasing consumption rates in Europe. Cocaine use is associated with great harm to individuals and society. As of today, psychotherapeutic interventions for cocaine use disorder (CUD) demonstrate only modest effect sizes, and no pharmacotherapy has been approved due to gaps in understanding the disease. However, a novel...

DOI: 10.1186/s13063-025-08982-9 (opens in new tab) Ketamine Neuroplasticity Boosting machine learning Protocol science +5

Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation.

Brain Sciences September 12, 2025 Krista Ulisse, Jehad Albitar, Jourdan Aromin et al. 5 citations

Addiction remains a persistent public health crisis, marked by poor treatment retention and limited pharmacotherapy options. Emerging treatments, such as psychedelic-assisted psychotherapy and neuromodulation, offer promising avenues for circuit-level interventions in behavioral addictions. This narrative review synthesizes the current landscape of psychedelic compounds and neuromodulation...

DOI: 10.3390/brainsci15090980 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Psychedelics & neuromodulation Brain stimulation Novel treatments +17

Mindfulness-Oriented Recovery Enhancement Reduces Illicit Substance Craving Among People with Alcohol Use Disorder and Polysubstance Use.

Substance Use & Misuse September 2, 2025 Laura Gurrieri, Margaret C. Wardle, Eric L Garland

Background: Polysubstance use is common in alcohol use disorder (AUD) and associated with poor treatment outcomes. Cannabis and cocaine often co-used with alcohol, have no approved medication treatments and respond poorly to common behavioral treatments. Thus, treatments that can reduce use of these substances alongside AUD are critically needed. Objectives: We tested whether...

Psychedelics for substance use disorders: are women being addressed? A scoping review

International Journal of Drug Policy September 2, 2025 Alexandra Wojdyslawski Nigri, Ilana Falcão de Arruda, Catarina Maia et al. 3 citations

INTRODUCTION: Substance use disorders (SUDs) are a prevalent health issue that affects individuals globally. Research is currently being conducted on the potential use of psychedelics as a new approach to treating SUDs. Women have been shown to respond differently than men to SUDs treatments and women-specific approaches have been recommended. This scoping review explores the ways in which...

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology September 2, 2025 Lucas M Wittenkeller, Gary A. Gudelsky, Theresa Winhusen et al. 3 citations

Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive processes with lasting effects. We aimed to characterise how psychedelics are currently being investigated to treat substance use disorders (SUDs). Additionally, we aimed...

Targeting Internet Addiction Through Body Awareness Psychotherapy: The Mediating Role of Executive Functions and Emotion Regulation.

Brain and Behavior September 1, 2025 Maliheh Fallah, Hamidreza Mohajerani, Abdullah Omidi et al.

Internet addiction disorder (IAD) is increasingly recognized as a behavioral addiction linked to deficits in executive functioning, emotion regulation, boredom susceptibility, and impaired time perception. Emerging therapies such as body awareness psychotherapy (BAP) aim to improve cognitive and emotional self-regulation through embodied mindfulness. This study aimed to assess the effectiveness...

DOI: 10.1002/brb3.70846 (opens in new tab) Full text (opens in new tab) Body awareness psychotherapy Cognitive function Emotion regulation Internet addiction +1

Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review.

NeuroSci August 27, 2025 Alexander Thomas, R Andrew Chambers 4 citations

Interest in ketamine as a novel treatment for substance use disorders (SUDs) has been increasing due to its N-methyl-D-aspartate (NMDA) glutamate receptor antagonism and mounting evidence that glutamate neurotransmission is involved in the pathogenesis of both depression and addictions. This narrative review provides an outline of clinical evidence reported in the literature from the 1970s to...

DOI: 10.3390/neurosci6030083 (opens in new tab) Full text (opens in new tab) Ketamine Nmda n-methyl-d-aspartate Case reports Cohort studies +3

Reconsidering Ibogaine for the treatment of severe mental illness and substance use disorders

Journal of Medicine Surgery and Public Health August 25, 2025 R. Andrew Yockey 2 citations

Severe mental illness (SMI) and co-occurring substance use disorders (SUDs) continue to pose a major global health challenge, contributing to high rates of mortality, disability, and economic strain. Ibogaine, a naturally occurring psychoactive compound derived from the Tabernanthe iboga plant, has shown promise in easing withdrawal symptoms, reducing cravings, and improving psychiatric...

DOI: 10.1016/j.glmedi.2025.100213 (opens in new tab) Mental illness Substance use Psychotherapist Mental health

Effect of Sookshma Meditation on Internet Addiction, Emotional Regulation, and Mindfulness in School Children: A Randomized Controlled Trial

Indian Journal of Science and Technology August 23, 2025 Chanchal Surywanshi, Ashween Bilagi, Meghnath Verma et al.

Objectives: To determine the effect of Sookshma Meditation (SM) on Internet Addiction (IA), Emotional Regulation (ER), and Mindfulness in School Children- A randomized controlled trial. Methods: A randomized control trial designed to assess the effect of SM (Meditation-based Yoga practices) on IA, ER, and Mindfulness in school-going children. After screening, 80 school-going children (44 boys &...

Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression

The American Journal of Drug and Alcohol Abuse August 22, 2025 P. Manza, Annabelle M. Belcher, Heather Fitzsimons et al.

ABSTRACT Background: Opioid use disorder (OUD) is a chronic relapsing condition with a high mortality rate. While medications such as methadone are valuable first-line therapies, retention is poor, with the highest dropout rates early in a treatment attempt. Poor outcomes are due in part to the very high rates of co-morbid depression in people with OUD, as depression can drive opioid use....

Antidepressant Efficacy of Ketamine Plus Naltrexone for Major Depression Comorbid with Alcohol Use Disorder: A Randomized Controlled Trial.

The International Journal of Neuropsychopharmacology August 11, 2025 Gihyun Yoon, Brian Pittman, E. Ralevski et al.

IMPORTANCE The comorbidity of major depressive disorder (MDD) and alcohol use disorder (AUD) is often treated inadequately. This study evaluated the impact of adding the opioid receptor blocker, naltrexone, to the NMDA glutamate receptor antagonist, ketamine, for the treatment of MDD comorbid with AUD. In so doing, it also attempted to shed light on the contribution of opioid receptor...

Longitudinal Effects of Interoceptive Awareness Training as an Adjunct to Medication Treatment for Opioid Use Disorder: A Randomized Clinical Trial of Mindful Awareness in Body-oriented Therapy

Drug and Alcohol Dependence August 1, 2025 Cynthia J. Price, Kenneth C Pike, Joseph O Merrill

Background and Objective: Medication for opioid use disorder (MOUD) treatment outcomes can be limited by co-occurring mental and physical conditions, and new adjunctive interventions are needed to improve treatment. Mindful Awareness in Body-oriented Therapy (MABT) teaches interoceptive awareness skills to promote well-being. This study evaluated the longitudinal effects of MABT as an adjunct...

Advances in the study of pharmacotherapy for addiction to naturally-derived psychoactive substances.

Chinese journal of natural medicines August 2025 Kexin Xie, Deli Xiao, Peng Xu et al.

Drug addiction, a disorder characterized by chronic relapse and compulsive drug use, poses a significant threat to public safety and human health. Addictive substances can be categorized as natural, semi-synthetic, or synthetic based on their origin. Additionally, they can be classified into three groups according to their pharmacological targets: opioids, hallucinogens, and cannabinoids that...

169. THERAPEUTIC MEMORY RECONSOLIDATION AS A TREATMENT FOR SUBSTANCE USE DISORDERS AND HOW PSYCHEDELICS ARE FACILITATING THIS INTERVENTION: THE UNITY STUDY

The International Journal of Neuropsychopharmacology August 1, 2025 S. Ofori, R. Das

Abstract Background Maladaptive motivational memory (MMM) is the term given to a learned association between environmental predictors of reward (cues) and the receipt of rewarding stimuli (reward). A key characteristic of MMMs is that they drive excessive consumption behaviours in a variety of disorders such as substance use disorders (SUDs) and behavioural addictions. MMMs underlie the...

Role of ketamine in the treatment of substance use disorders: A systematic review.

Journal of Substance Use and Addiction Treatment August 1, 2025 Reinhard Janssen-Aguilar, Shakila Meshkat, Ilya Demchenko et al. 12 citations

Substance Use Disorders (SUDs) involve diminished control, risky use, impaired social interactions, and physical dependence. Despite their global prevalence and burden, treatment options remain limited. Ketamine (KET), an NMDA receptor antagonist, may aid SUD treatment by modulating glutamatergic neurotransmission. This systematic review evaluates KET's role in SUD treatment. This review...

DOI: 10.1016/j.josat.2025.209705 (opens in new tab) Full text (opens in new tab) Sud Systematic review Addiction treatment Ketamine therapy +3